Tagrisso (osimertinib) received approval as an adjuvant treatment for patients with non-small cell lung cancer with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations, the U.S. Food and Drug ...
Dec 23, 2020
0
5
The best treatment for a genetically driven form of lung cancer continues to show lasting benefits, a new clinical trial update shows.
Feb 6, 2023
0
2
A new research paper was published in Oncotarget entitled, "Mutation analysis performed on tumor biopsies from patients with newly-diagnosed germinal center aggressive B cell lymphomas."
Nov 17, 2022
0
2
Pancreatic cancer remains one of the deadliest malignancies worldwide. Since five-year survival rate for pancreatic ductal adenocarcinoma (PDAC) is only about 3% in patients, PDAC is very difficult to treat with surgery worldwide. ...
Dec 15, 2022
0
31
(HealthDay)—The combination of pembrolizumab and axitinib has been approved as a first-line treatment in advanced renal cell carcinoma (RCC), the U.S. Food and Drug Administration announced Friday.
Apr 23, 2019
0
2
The traditional treatment for early-stage non-small cell lung cancer is a lobectomy, where a surgeon eradicates cancerous tissue by removing an entire lung lobe.
Mar 24, 2023
0
36
Researchers, led by Pennington Biomedical Research Center's Dr. Justin Brown, have found that physical activity can prevent, and not just delay, cancer recurrence in patients previously treated for colon cancer.
Mar 21, 2023
0
2
Among patients with hormone receptor-positive breast cancer treated with an aromatase inhibitor plus palbociclib (Ibrance), those who displayed a rising ESR1 mutation detected in their blood before disease progression doubled ...
Dec 9, 2021
0
3
Progression-free survival is significantly longer with zanubrutinib than ibrutinib among patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), according to a study published ...
Jan 3, 2023
0
7
The E2810 research study was conducted to determine whether taking the oral drug pazopanib (Votrient) following surgery to remove further metastases in patients with advanced renal cell carcinoma would improve their disease-free ...
Jun 3, 2019
0
2
